文献速递血栓与止血

快速免疫测定序贯组合用于肝素诱导性血小板减少症的即时识别

Sequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopenia.
PubMed 文献 · Blood · 2025-01-01

研究纳入1194例疑似肝素诱导性血小板减少症(HIT)患者,确诊率6.0%,验证两种贝叶斯序贯组合快速免疫测定法并与Hamilton及TORADI-HIT算法比较诊断性能。序贯法正确排除HIT达95.6%和96.4%,预测HIT达95.8%和97.2%,无假阴性。

要点

  • 序贯组合两种快速免疫测定(CLIA先行、LIA用于15-20%未解决病例,或反之)可正确排除HIT 95.6%和96.4%。
  • 该序贯法预测HIT达95.8%和97.2%,分别有13和15例假阳性,无假阴性。
  • TORADI-HIT算法正确排除HIT 97.9%,但假阴性率6%,漏诊HIT病例。

核心结论

  • 序贯使用两种免疫测定的贝叶斯方法对HIT诊断准确,可在1小时内对≥97%的病例完成HIT排除或识别。
  • 同时进行免疫测定而不考虑临床验前概率会漏诊HIT病例。

研究设计与样本

  • 纳入1194例疑似HIT患者,其中6.0%确诊HIT。
  • 采用HemosIL Acustar HIT-IgG(化学发光免疫测定,CLIA)和HemosIL HIT-Ab(乳胶免疫比浊测定,LIA)。
  • 以肝素诱导血小板活化(HIPA)试验和血小板因子4增强HIPA(PIPA)作为HIT确诊或排除的金标准。
  • 验证两种贝叶斯序贯组合方法,并与Hamilton算法和TORADI-HIT算法比较诊断性能。

主要发现

  • 序贯法(CLIA先行、LIA用于15-20%未解决病例)正确排除HIT 95.6%,预测HIT 95.8%,3.3%病例未确定,13例假阳性,无假阴性。
  • 序贯法(LIA先行、CLIA用于15-20%未解决病例)正确排除HIT 96.4%,预测HIT 97.2%,2.3%病例未确定,15例假阳性,无假阴性。
  • 改良Hamilton算法正确排除HIT 92.1%,预测HIT 97.2%,88例假阳性,2例假阴性。
  • TORADI-HIT算法正确排除HIT 97.9%,预测HIT 93.8%,10例假阳性,3例假阴性。

临床怎么用

  • 采用贝叶斯序贯组合两种快速免疫测定可在1小时内对≥97%的病例完成HIT排除或识别。
  • 同时进行免疫测定而不考虑临床验前概率会漏诊HIT病例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early recognition and treatment of heparin-induced thrombocytopenia (HIT) are crucial to prevent severe complications. Although immunoassays offer rapid diagnosis, their sensitivity and specificity are suboptimal. Sequential combinations of quantitative immunoassay results improve their diagnostic accuracy. We aimed to validate 2 Bayesian approaches combining 2 rapid immunoassays and to compare their diagnostic performance with 2 other diagnostic approaches (Hamilton and TORADI-HIT algorithms). We included 1194 patients with suspected HIT, of whom 6.0% had confirmed HIT. HemosIL Acustar HIT-IgG (chemiluminescent immune assay [CLIA]) and HemosIL HIT-Ab (latex immune-turbidimetric assay [LIA]) (Instrumentation Laboratory, Munich, Germany) were performed. Definite HIT confirmation or exclusion was made using heparin-induced platelet activation (HIPA) test and platelet factor 4-enhanced HIPA (PIPA). Our sequential approaches (CLIA first and LIA for 15-20% unsolved cases or vice versa) correctly excluded HIT in 95.6% and 96.4%, predicted HIT in 95.8% and 97.2%, with 3.3% and 2.3% of cases remaining undetermined; there were no false-negative predictions, and 13 and 15 false-positive predictions, respectively The modified version of the Hamilton algorithm correctly excluded HIT in 92.1% and predicted HIT in 97.2% with 88 false-positive and 2 false-negative results. The TORADI-HIT algorithm correctly excluded HIT in 97.9% and predicted HIT in 93.8% (10 false positives, 3 false negatives). In conclusion, a Bayesian approach sequentially using 2 immunoassays is accurate for HIT diagnosis. Performing immunoassays simultaneously without considering clinical pretest probability misses HIT cases. The TORADI-HIT algorithm offers better HIT exclusion with a 6% false-negative rate. Using our Bayesian approach, HIT exclusion or recognition can be achieved in ≥97% of cases within <1 hour.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Steinauer T, Matthey-Guirao E, Gomez FJ, et al. Sequential combinations of rapid immunoassays for prompt recognition of heparin-induced thrombocytopenia. Blood. 2025. PMID: 40403233. doi:10.1182/blood.2024027517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。